Fierce Pharma
ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data
Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...
Pfizer Inc. (PFE) announces results from the phase 3 BASIS study evaluating HYMPAVZI
Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results ...
Pfizer's Hemophilia Drug Data Signals Strategic Shift
The Phase 3 "BASIS" trial data, showcased at the American Society of Hematology (ASH) annual meeting, showed significant promise. For patients with inhibitors—a subgroup historically difficult to ...
NBC News
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The agency ...
HYMPAVZI(R) (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...
Mirage News
HYMPAVZI Cuts Bleeds 93% in Hemophilia A/B With Inhibitors
Pfizer Inc. (NYSE: PFE)today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and ...
Pfizer Inc. (PFE) announces results from phase 3 BASIS study
Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results ...